{"id":"rituximab-chlorambucil","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion-related reactions"},{"rate":"20-30%","effect":"Neutropenia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"10-20%","effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rituximab works by binding to the CD20 antigen on the surface of B cells, marking them for destruction by the immune system. Chlorambucil, on the other hand, damages the DNA of rapidly dividing cells, including cancer cells, thereby inhibiting their growth and proliferation.","oneSentence":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while chlorambucil is an alkylating agent that interferes with DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:21.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Follicular lymphoma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04075292","phase":"PHASE3","title":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-01-20","conditions":"Untreated Chronic Lymphocytic Leukemia","enrollment":155},{"nctId":"NCT01808599","phase":"PHASE2","title":"Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2013-12","conditions":"MALT Lymphoma","enrollment":112},{"nctId":"NCT06319456","phase":"PHASE3","title":"A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-04-07","conditions":"CLL/SLL","enrollment":344},{"nctId":"NCT04578613","phase":"PHASE3","title":"ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2021-01-08","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":218},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT00875667","phase":"PHASE2","title":"A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-04-30","conditions":"Mantle Cell Lymphoma, Lymphoma, Mantle-Cell","enrollment":254},{"nctId":"NCT00210353","phase":"PHASE3","title":"Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2003-01","conditions":"Lymphoma, Mucosa-Associated Lymphoid Tissue","enrollment":454},{"nctId":"NCT03881592","phase":"","title":"Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness","status":"UNKNOWN","sponsor":"Brno University Hospital","startDate":"2018-11-01","conditions":"Chronic Lymphocytic Leukemia","enrollment":400},{"nctId":"NCT01283386","phase":"PHASE4","title":"A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-27","conditions":"Lymphocytic Leukemia, Chronic","enrollment":26},{"nctId":"NCT01010061","phase":"PHASE3","title":"CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12-21","conditions":"Lymphocytic Leukemia, Chronic","enrollment":787},{"nctId":"NCT02053610","phase":"PHASE3","title":"CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12-31","conditions":"Lymphocytic Leukemia, Chronic","enrollment":787},{"nctId":"NCT01998880","phase":"PHASE3","title":"CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12-22","conditions":"Lymphocytic Leukemia, Chronic","enrollment":787},{"nctId":"NCT01862445","phase":"","title":"Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2013-10","conditions":"CLL, B-cell, Small Lymphocytic Lymphoma","enrollment":100},{"nctId":"NCT00738374","phase":"PHASE2","title":"A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-03","conditions":"Lymphocytic Leukemia, Chronic","enrollment":97},{"nctId":"NCT00532129","phase":"PHASE2","title":"A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Lymphocytic Leukemia, Chronic","enrollment":100},{"nctId":"NCT00250718","phase":"PHASE2","title":"Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2004-10","conditions":"Non-Hodgkin's Lymphoma, Cancer","enrollment":17},{"nctId":"NCT01056510","phase":"PHASE4","title":"A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Lymphocytic Leukemia, Chronic","enrollment":357},{"nctId":"NCT00285389","phase":"PHASE2","title":"Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2002-02","conditions":"Mantle Cell Lymphoma","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rituximab+chlorambucil","genericName":"rituximab+chlorambucil","companyName":"International Extranodal Lymphoma Study Group (IELSG)","companyId":"international-extranodal-lymphoma-study-group-ielsg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while chlorambucil is an alkylating agent that interferes with DNA replication. Used for Follicular lymphoma, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}